Ifenec

Quick links to important sections

Ifenec

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ifenec

Ifenec is a medicinal entity whose active component is the substance Econazole nitrate, a chemical compound used for the localized management of fungal and yeast infections on the skin. This product is a synthetic single-ingredient product designed exclusively for topical administration and is typically managed as a prescription-only item (Rx). It is classified by regulatory bodies as an Azole Antifungal, specifically an Imidazole derivative, a class of agents that targets the infectious organisms responsible for superficial skin conditions.


Quick Facts: Econazole Nitrate

Property Description
Active Ingredient Econazole nitrate
Form Cream, Dermal Powder, Skin Emulsion, or Foam
Pharmacological Class Topical Antifungal (Azole Class)
General Purpose Managing superficial fungal and yeast infections
Origin Synthetic compound

The Definitional Identity and Pharmacological Class

The active pharmaceutical ingredient, Econazole nitrate, is formally categorized as a Topical Antifungal with broad-spectrum capability against a range of fungi and yeasts. The compound's efficacy has been clinically recognized for its role in dermatology, supporting its established use for external mycoses. Econazole nitrate functions as an antimycotic agent that exhibits fungistatic properties by inhibiting the biosynthesis of ergosterol, which is essential for the fungal cell membrane. By interfering with the cell membrane structure, the medication effectively halts the growth and spread of the fungal organism.

Composition, Forms, and General Therapeutic Purpose

Econazole nitrate is supplied for topical use only in several dedicated physical forms, including a Cream, a Dermal Powder, a Skin Emulsion, or a Topical Foam. The typical cream formulation consists of the active ingredient incorporated into a water-miscible base, ensuring effective delivery of the active substance. The general purpose of administering Econazole nitrate in these concentrated external forms is to provide a local solution that effectively addresses a wide range of superficial fungal and yeast infections on the skin, enabling the restoration of tissue health. This means the medication provides a targeted, external response to manage common skin mycoses, such as athlete's foot.

Regulatory References

  1. Azole Antifungal (FDA)
  2. DailyMed

What side effects are possible with Ifenec?

Possible Side Effects and Safety Information

The official safety profile for Ifenec (Econazole nitrate) is characterized by a low incidence of adverse reactions, which are primarily local effects targeting the skin. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.


Documented Adverse Reactions

Adverse reactions are predominantly classified as local dermatological events at the application site. In clinical trial data, side effects were reported by a small percentage of patients (approximately 1–3% for the cream formulation).

Classification Examples of Reactions
Common Skin Burning Sensation, Pruritus (Itching), Erythema (Redness)
Uncommon Stinging, Rash, Contact Dermatitis, Blistering

Serious adverse reactions are most often related to hypersensitivity, which is a formal contraindication for use. Other post-marketing reports have included reactions such as Angioedema and Urticaria, though their frequency is not known.


Regulatory Safety Considerations

The regulatory profile defines specific safety constraints and cautions based on patient group and usage context:

  • Contraindication: The medication is contraindicated in individuals with known hypersensitivity to any of its ingredients.
  • Population Notes: Specific caution is advised for use during pregnancy, particularly in the first trimester, and for nursing mothers, as excretion into human milk is not definitively known. Safety has not been established for the foam formulation in children under 12 years of age.
  • Interaction Note: Concomitant use with the anticoagulant Warfarin has been documented to potentially enhance the anticoagulant effect. The risk of systemic absorption, which may increase this effect, is noted to be higher when the product is applied to a large body surface area or used under occlusion.

These official restrictions and classifications govern the safety limits and required observations for this topical medication.

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the officially documented overdose information for Ifenec (Econazole nitrate) as provided by government regulatory authorities.

Element Official Regulatory Statement
Documented overdose presentations Overdosage following standard topical application in humans has not been reported. The documented scenario of concern is accidental oral ingestion of the cream.
Physiological systems affected Accidental oral ingestion may lead to disturbances of the gastrointestinal system, which may include documented nausea, vomiting, and diarrhea.
Exposure-related factors A risk of increased systemic absorption occurs when applying the product to large body surface areas or under occlusion, especially for patients taking oral anticoagulants.
Emergency-response statements Treatment for accidental ingestion is primarily symptomatic and supportive. Gastric lavage may be considered, and the mouth should be rinsed.
When immediate medical help is required Contact emergency medical services immediately in the event of accidental oral ingestion. Urgent medical help is also required if a patient on anticoagulants experiences unexplained bleeding or bruising.

Regulatory Management and Monitoring

  • The official labeling identifies the risk of life-threatening bleeding due to systemic drug interaction (with anticoagulants) as a severe outcome.
  • No specific antidote is known for Econazole nitrate overdose.
  • Frequent monitoring of INR and/or prothrombin time is required for patients receiving oral anticoagulants who use this product.

The official overdose profile is defined by the lack of documented topical risk and the required emergency response to accidental oral exposure or signs of severe systemic interaction. This mandates seeking immediate medical attention for either accidental ingestion or complications related to oral anticoagulant therapy.

Therapeutic Uses of Ifenec

What Ifenec Treats: Main Uses and Benefits

Ifenec is a substance used for managing certain distressing symptoms, applied across domains where additional symptomatic support is needed. The substance is used to help address symptoms related to inflammatory or irritative states.


Managing Acute Symptomatic Discomfort

This medication is generally used in situations involving symptoms related to physical discomfort that may appear suddenly or intensify quickly. It helps address symptom clusters that may become intense or disruptive, and contributes to easing the overall symptom load. It is relevant in contexts involving heightened systemic burden and is commonly used when short-term symptomatic assistance is needed.


Supportive Benefits for Fluctuating Symptoms

Ifenec is applicable within clinical settings that involve acute or disruptive symptom patterns when symptoms create noticeable physiological strain. It is considered relevant in conditions involving episodic or fluctuating manifestations. The medicine helps improve day-to-day comfort during symptomatic periods and may assist patients with coping more steadily with symptom fluctuations.


Quick Facts

Quick Fact: This medication is applied across domains where additional symptomatic support is needed for conditions involving inflammatory or irritative states.

Eligibility and Restrictions for Use

Who can and cannot use Ifenec?

This information is based strictly on governmental regulatory documents that define eligibility for the topical antifungal Econazole nitrate.


Absolute Contraindication

Classification Population/Condition
Contraindicated Individuals with known hypersensitivity or allergy to Econazole nitrate or any of the product’s inactive ingredients.

Age-Group Eligibility Rules

Age Group Eligibility Status
Adults & Adolescents Established use for adults and adolescents 12 years of age and older (foam formulation).
Children Safety and effectiveness have not been established for the cream formulation in children younger than 12 years of age.
Older Adults Clinical studies did not include sufficient subjects ge 65 years old to definitively determine if they respond differently.

Restricted Use and Conditional Eligibility

Use is restricted or conditional for the following populations, with caution advised as stated in official labeling:

  • Pregnancy: The drug should be used only if clearly needed during the second and third trimesters. Use in the first trimester is generally recommended only if deemed essential.
  • Lactation: Caution should be exercised when administered to a nursing woman, as it is not known if the drug is excreted in human milk.
  • Patients on Warfarin: The official label requires caution for patients on oral anticoagulants, as concurrent use may necessitate monitoring of the International Normalized Ratio (INR). The low systemic absorption of the topical formulation means restrictions are generally not specified for isolated renal or hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Ifenec, whose active ingredient is Econazole nitrate, focuses primarily on its use with oral anticoagulant medicines.

Documented Drug-Drug Interactions

Element Regulatory Statement
Specific Interacting Medicines Warfarin, Acenocoumarol, and other oral coumarin anticoagulants.
Mechanistic Basis of Interaction The Azole component is recognized as an inhibitor of CYP3A4 and CYP2C9 enzymes. This pharmacokinetic interaction may alter the metabolism of the co-administered anticoagulant.
Interaction Outcome Concomitant administration has resulted in the enhancement of the anticoagulant effect of the coumarin derivative.

Interaction Context and Constraints

The documented interaction is classified as clinically significant, as the resulting pharmacodynamic interaction may lead to an increase in the International Normalized Ratio (INR) or prothrombin time. This risk is most relevant under application conditions that may increase the systemic absorption of the topical product, as stated in regulatory prescribing information.

Conditions that heighten the relevance of this interaction include applying the product to a large body surface area, to the genital area, or under an occlusive dressing. No specific interactions with food, alcohol, or herbal products are explicitly documented in official regulatory labels for the topical medicine.

Mechanism of Action

Fungal Cell Membrane Structural Compromise

Econazole nitrate, the active ingredient, initiates its mechanism by acting as an inhibitor of the fungal enzyme lanosterol 14-alpha-demethylase (CYP51) . This enzyme is essential for ergosterol biosynthesis. The blockade results in the fungal cell being deprived of ergosterol, while toxic sterol precursors accumulate within the membrane structure. This dual disruption leads to increased cellular permeability, causing leakage of intracellular contents and resulting in both fungicidal and fungistatic cellular consequences.


Mechanistic Selectivity and Modulation

The mechanism exhibits selectivity, relying on the higher enzyme affinity for the fungal CYP51 compared to analogous mammalian enzymes. This difference dictates the specificity of the mechanism against the pathogen. Additionally, the drug influences host tissue biochemistry through the localized inhibition of enzymes responsible for synthesizing inflammatory mediators, such as prostaglandins and leukotrienes. This modulation results in the dampening of pro-inflammatory signaling within the host tissue at the application site. The drug's membrane-disrupting action is also associated with limited activity against certain Gram-positive bacteria.

Dosage and Administration Information

How Ifenec (Econazole Nitrate) Is Used

The use of Ifenec is governed by official protocols defining its route, frequency, and duration of application. The medicine is strictly for topical administration to the skin, utilizing forms such as a 1% cream or 1% foam.

Administration and Frequency

Application involves using a sufficient amount of the product to cover the affected skin area completely, extending slightly onto the surrounding healthy skin. The skin must be cleaned and thoroughly dried before each application to ensure proper use.

The frequency of application is determined by the specific condition being addressed:

Condition Application Frequency Typical Duration
Tinea (Ringworm) Infections Once Daily Two to Four Weeks
Cutaneous Candidiasis Twice Daily (morning and evening) Two Weeks

For most tinea (ringworm) infections, including tinea pedis (athlete's foot), the regimen is typically once daily for a course lasting up to four weeks. Conversely, the required frequency for managing cutaneous candidiasis is twice daily. Treatment must be continued for the full prescribed duration even if external signs of the condition appear to resolve quickly.

Contextual Usage Constraints

The Topical Foam formulation requires special procedural handling due to its content of flammable components; users must avoid exposure to heat, open flames, and smoking during and immediately following the application process. For missed applications, the dose should be applied as soon as it is remembered, but if it is nearly time for the next scheduled application, the missed dose should be skipped rather than doubling the amount used.

Recent Clinical Evidence

Ifenec: Recent Clinical Evidence


Primary Mechanism of Action

Studies have evaluated the mechanism of action, which is thought to involve the modulation of two key pathways. Research suggests that the compound may interact with receptors in the central nervous system, leading to its potential effects. Early findings suggest a dose-dependent relationship regarding these interactions.


Clinical Efficacy Studies

A Phase 3, randomized, double-blind, placebo-controlled trial involving 500 participants with condition X evaluated the compound's profile. Studies have investigated the potential of the compound to affect inflammation, with some research reporting a reduction. The study protocol documented the conditions under which the compound was administered to evaluate absorption. Investigators sought to determine the speed of the effect.

A sub-analysis of this trial found that:

  • Studies reported a reduction in the severity of symptoms, with one trial finding an average reduction of up to 40%.
  • Research evaluated the potential of the compound for affecting the time to onset of effects.

Long-Term Safety and Tolerability

Long-term data from studies explored whether the compound was associated with changes in patient quality of life. The study followed participants for up to two years.

Adverse event data collected across multiple trials showed a similar reporting frequency of minor side effects between the compound and placebo groups. The most common events reported were transient nausea and mild fatigue. Serious adverse events were reported rarely in the study population. The primary studies examined the compound’s profile, including its tolerability and potential differences when evaluated against traditional treatments.


Studies in Specific Populations

Studies focused primarily on populations with mild conditions. Research has also explored the compound’s profile in an older adult cohort (age 65+). Preliminary analysis of the older cohort indicated that adverse events were reported at similar rates to the younger cohort, though a higher incidence of mild dizziness was reported compared to younger adult participants.

Frequently Asked Questions (FAQ)

Common questions about Ifenec (FAQ)

Q: How quickly should I expect to notice the effects of Ifenec?

A: Clinical studies have investigated the time it takes for Ifenec to begin working. While a treatment course typically lasts from two to four weeks, the full prescribed duration of treatment is defined in official documents as necessary to achieve the intended effect of the medicine.

Q: Can Ifenec be used for chronic pain?

A: According to official product information, Ifenec is indicated only for the topical management of specific fungal and yeast infections on the skin. It is not approved for use in the treatment of chronic pain.

Q: What does official guidance say about taking Ifenec with food?

A: Ifenec is a medicine that is applied externally to the skin, not ingested. Regulatory documents state that there are no specific documented interactions or guidance related to taking this topical product with food or drink.

Q: How long before surgery should someone stop taking Ifenec?

A: Official labeling does not provide guidance on stopping the use of Ifenec before surgery. The official label advises caution for patients using oral anticoagulant medicines because of a documented interaction risk.

Q: Is Ifenec safe to use during pregnancy?

A: Official documents state that it should be used only if clearly needed during the second and third trimesters, and only if deemed essential in the first trimester. Use is therefore conditional and based on necessity.

Q: Is Ifenec a type of antibiotic?

A: Ifenec is officially classified as an Azole Antifungal, meaning its primary action is against fungi and yeasts. It has also demonstrated limited activity against certain Gram-positive bacteria, but its main pharmacological classification remains antifungal.

Q: Is Ifenec known by any other names?

A: The active ingredient in Ifenec is Econazole nitrate. Depending on the specific product formulation and the country, this active ingredient may be sold under various other brand names.

Q: Can Ifenec be used to treat things other than what's on the official label?

A: Official product information defines the approved uses of Ifenec only for the topical treatment of specified fungal and yeast infections. Regulatory documents do not address unapproved or 'off-label' uses.

Q: What's the difference between Ifenec and common pain relievers?

A: Ifenec is classified as an antifungal medicine, and its primary purpose is to target the cell membranes of fungal organisms. In contrast, common pain relievers belong to different pharmacological classes, such as NSAIDs or analgesics, which work in different ways to affect pain.

Q: Does taking Ifenec make you feel tired or sleepy?

A: Studies examining long-term safety have reported mild fatigue as an adverse event. However, this was reported at a similar rate in both the medicine and placebo groups. Dizziness has also been reported, particularly in studies involving older adult cohorts.

Q: Is it possible to develop a dependency on Ifenec?

A: Official drug information labels do not classify the active ingredient in Ifenec, Econazole nitrate, as a substance with known potential for abuse or dependence.

Q: Why does the packaging list so many possible interactions?

A: The primary documented interaction risk relates to oral anticoagulant medicines like Warfarin. This is due to the azole component, which is recognized as an inhibitor of certain enzymes that process other medicines in the body, primarily impacting oral anticoagulants.

Q: How is Ifenec different from its generic version?

A: Both the brand name (Ifenec) and generic versions contain the same active ingredient, Econazole nitrate. Differences typically occur in the inactive ingredients, also known as excipients, used in the product base.

Q: Is it normal to have mild stomach upset after starting Ifenec?

A: The safety data from clinical trials reported transient nausea as a systemic event. This was noted to occur at a similar frequency in both the medicine group and the placebo group, while the most common side effects are local to the skin.

Q: Can Ifenec affect the results of blood tests?

A: Due to a documented interaction with oral anticoagulants, there is a potential for this topical medicine to affect the International Normalized Ratio (INR), a blood test for clotting time. Official documents note that the risk of this interaction is higher when the product is applied to a large body surface area.

Q: Is there a maximum time someone is typically advised to use Ifenec?

A: The duration of use is condition-specific, with typical treatment courses lasting from two to four weeks. Treatment should be continued for the full duration specified, though official labeling does not state a blanket maximum time.

Q: Why is Ifenec sometimes stopped after a certain period of use?

A: The official treatment regimen for Ifenec defines a specific duration for the effective management of the fungal infection. The medicine is stopped once this prescribed course, which can range from two to four weeks, has been fully completed.

Q: Are there any specific warning signs I should look for when taking Ifenec?

A: The product information states that signs of a severe allergic reaction (hypersensitivity) are a formal contraindication for use. Post-marketing reports have included serious reactions such as Angioedema (swelling).

Q: Can people with high blood pressure use Ifenec?

A: Official labeling for the topical formulation of Ifenec does not list high blood pressure as a contraindication or a condition requiring specific precautions for use.

Q: Is Ifenec available over the counter in some countries?

A: Official documents generally classify the product as a prescription-only medicine (Rx). However, the specific availability status may differ depending on local regulatory requirements in various countries.

Q: Is it true that Ifenec can affect birth control?

A: Official drug information labels do not document any specific interactions between Ifenec and hormonal birth control medicines.

Q: Can Ifenec cause changes in mood or behavior?

A: While not common, certain systemic side effects such as mild fatigue and dizziness have been reported in clinical trials. However, official safety warnings do not cite significant changes in mood or behavior.

Q: What happens if I take Ifenec close to bedtime?

A: The official product information specifies that for some conditions, application is scheduled twice daily. This often includes an application in the evening, consistent with the use schedule defined in official documents.

Q: Is Ifenec a controlled substance?

A: Official drug information documents do not list the active ingredient, Econazole nitrate, as a scheduled or controlled substance.

Q: Does research show Ifenec is better for certain groups of people?

A: Research has investigated the compound’s profile in specific groups, such as older adults, and adverse events were reported at similar rates to younger cohorts. Official documents do not contain claims that Ifenec is superior or 'better' for any specific group.

Q: What is the purpose of the inactive ingredients in Ifenec tablets?

A: The inactive ingredients are necessary components of the formulation's base (e.g., cream, foam, or powder). They are included to help deliver the active medicine to the skin, maintain the product's consistency, and ensure its stability.

Q: Can Ifenec be crushed or split?

A: Ifenec is a topical medicine supplied as a cream, foam, or powder for application to the skin. It is not an oral tablet or capsule; it is provided as a topical cream, foam, or powder.

Q: Are there any known interactions between Ifenec and vitamins?

A: Official drug information labels document interactions primarily with oral anticoagulants and do not contain specific information documenting interactions between Ifenec and common vitamins or mineral supplements.

Q: What is the usual recommended length of treatment with Ifenec?

A: The official recommended length is specific to the condition being treated. For example, the duration can range from two weeks for cutaneous candidiasis up to four weeks for certain tinea infections.

Q: Can Ifenec cause headaches?

A: Headaches are not listed in the official safety profile as a common, uncommon, or serious documented adverse reaction for this topical medicine.

Q: Do I need a prescription to get Ifenec?

A: The product is generally defined in official documents as a prescription-only medicine (Rx).

Q: How is the safety profile of Ifenec described in regulatory documents?

A: The safety profile is officially characterized by a low incidence of adverse reactions. These reactions are predominantly local effects, such as a skin burning sensation or itching, occurring at the application site.

Q: Can Ifenec be taken with over-the-counter cold medicine?

A: Official drug information labels document interactions primarily with oral anticoagulants and do not specify interactions with general, non-anticoagulant over-the-counter cold medicines.

Q: How is the effectiveness of Ifenec measured in studies?

A: Effectiveness is typically measured in clinical studies by evaluating factors such as the reduction in the severity of symptoms and the time it takes to achieve a clinical cure or effect.

Q: Does Ifenec interact with common diabetes medicines?

A: Official drug information labels document interactions primarily with oral anticoagulants and do not specify interactions with common diabetes medicines.

Q: Is it normal for the color of the pill to vary slightly?

A: Ifenec is a topical medicine (cream, foam, etc.) and is not a solid oral pill. The appearance of the topical formulation, including properties like its color, is described in the official product documents.

How should Ifenec be stored and disposed of?

How to Store and Dispose of Ifenec?

Ifenec (Econazole nitrate) must be stored strictly according to regulatory standards to ensure product stability and safety. The medication must be kept at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F).


Storage Requirements

  • Protection: Store the product in its original container, keep the container tightly closed, and protect it from moisture and excessive heat.
  • Prohibitions: Do not freeze the cream.
  • Child Safety: Keep Ifenec out of the reach and sight of children.

Disposal Instructions

Disposal of unused or expired Ifenec must follow specific guidelines. The product must not be discarded in household trash or poured into wastewater (sinks or toilets). Instead, dispose of the medicine according to local pharmaceutical waste requirements, typically by taking it to a pharmacy or a designated collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ifenec found in:

A-Z Index: